• product_banner

Promote Drug Development Process – Bioantibody

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We depend on sturdy technical force and continually create sophisticated technologies to meet the demand of H Pylori Antibody Test Results, Pregnancy Test Results, Helicobacter Pylori Antibody Range, We adhere to the tenet of "Services of Standardization, to Meet Customers' Demands".
Promote Drug Development Process – Bioantibody Detail:

General Information

Bioantibody first-in-class and best-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage stimulating agents for patients worldwide.

History

The ground-breaking discovery of monoclonal antibody (mAb) technology by Kohler and Milstein in 1975 provided the possibility of creating antibodies as a class of therapeutics (Kohler & Milstein, 1975). Monoclonal antibodies (mAbs) are one of the most widely used drug platforms for infectious diseases or cancer therapeutics because they selectively target pathogens, infectious cells, cancerous cells, and even immune cells. In this way, they mediate the elimination of target molecules and cells with fewer side effects than other therapeutic modalities. In particular, cancer therapeutic mAbs can recognize cell-surface proteins on target cells and then kill the targeted cells by multiple mechanisms.
Humanization greatly reduces a therapeutic antibody’s immunogenicity in humans, making chronic administration possible. Such advances in antibody technologies have resulted in an explosion in the development of therapeutic mAbs over the last decade. A series of antibody derivatives, which include Fc-fusion proteins, antibody-drug conjugates (ADCs), immunocytokines (antibody-cytokine fusions), and antibody-enzyme fusions, are also developed and commericialized as a new treatment.

Drug effects

For patients, new targeted drugs mean fewer side effects, fewer hospitalizations, improved quality of life, increased productivity, and importantly, extended lives. But drug development is a long, complex process.

Reference

Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. doi: 10.1038/256495a0
Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9–14. doi: 10.4161/19420862.2015.989042.
Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):e00225. Published 2015 Jul 14. Available at https://pubmed.ncbi.nlm.nih.gov/26182432/. Accessed July 2020.
Reichert, J.M., and Valge-Archer, V.E. (2007). Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6, 349–356.
Lazar, G.A., Dang, W., Karki, S., Vafa, O., Peng, J.S., Hyun, L., Chan, C., Chung, H.S., Eivazi, A., Yoder, S.C., et al. (2006). Engineered antibody Fc variants with enhanced effector function. PNAS 103, 4005–4010.


Product detail pictures:

Promote Drug Development Process – Bioantibody detail pictures


Related Product Guide:

Our progress depends around the innovative machines, great talents and consistently strengthened technology forces for Promote Drug Development Process – Bioantibody , The product will supply to all over the world, such as: Germany, Uruguay, Ecuador, Our company is working by the operation principle of "integrity-based, cooperation created, people oriented, win-win cooperation". We hope we can have a friendly relationship with businessman from all over the world
  • As an international trading company, we have numerous partners, but about your company, I just want to say, you are really good, wide range, good quality, reasonable prices, warm and thoughtful service, advanced technology and equipment and workers have professional training, feedback and product update is timely, in short, this is a very pleasant cooperation, and we look forward to the next cooperation!
    5 Stars By Mamie from Honduras - 2018.07.26 16:51
    Products and services are very good, our leader is very satisfied with this procurement, it is better than we expected,
    5 Stars By Natalie from Swiss - 2017.08.15 12:36
    Write your message here and send it to us